Background: Contradictory evidence exists regarding statin use and risk of osteoporotic fractures. Objective: The study objective was to examine the effect of statins on fracture risk in a Military Healthcare System (MHS) with similar access and standard of health care for its beneficiaries. Methods: This is a retrospective study of patients enrolled in an MHS encompassing the period from October 1, 2003, to March 1, 2010. Statin users were defined as those receiving a statin for ≥90 days in Fiscal Year 2005, whereas nonusers were defined as individuals not receiving a statin throughout the study period. A propensity score–matched cohort of statin users and nonusers was created using 42 variables. The outcomes were identified using ICD-9-CM codes in the follow-up period (October 1, 2006, to March 1, 2010). In all, 4 outcomes were examined: all fractures, femoral neck fractures, upper-extremity fractures, and lower-extremity fractures. Results: Of 46 249 patients, 6967 pairs of statin users and nonusers were matched. Statin users had a lower risk of femoral neck fracture in comparison to nonusers (odds ratio = 0.58, 95% CI = 0.36-0.94) but similar risk of all fractures, lower-extremity fractures, and upper-extremity fractures. Conclusions: In this cohort of patients managed in an MHS, statin use was associated with a lower risk of femoral neck fractures, but not all fractures, upper-extremity fractures, or lower-extremity fractures.
CenterJRNguyenTVSchneiderDSambrookPNEismanJA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-882. doi:10.1016/S0140-6736(98)09075-8.
2.
HolroydCCooperCDennisonE. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22:671-685. doi:10.1016/j.beem.2008.06.001.
3.
LaneNE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2, suppl):S3-S11. doi:10.1016/j.ajog.2005.08.047.
4.
MojaLPiattiAPecoraroV. Timing matters in hip fracture surgery: patients operated within 48 hours have better outcomes. a meta-analysis and meta-regression of over 190,000 patients. PLoS One. 2012;7:e46175. doi:10.1371/journal.pone.0046175PONE-D-12-04093.
5.
SimunovicNDevereauxPJSpragueS. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010;182:1609-1616. doi:10.1503/cmaj.092220.
6.
CawstonHMaravicMFardelloneP. Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Arch Osteoporos. 2012;7(1-2):237-246. doi:10.1007/s11657-012-0102-3.
7.
GauthierAKanisJAJiangY. Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos. 2011;6(1-2):179-188. doi:10.1007/s11657-011-0063-y.
8.
ChanKAAndradeSEBolesM. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185-2188. doi:10.1016/S0140-6736(00)02400-4.
9.
MeierCRSchliengerRGKraenzlinMESchlegelBJickH. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-3210.
10.
PascoJAKotowiczMAHenryMJSandersKMNicholsonGC. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002;162:537-540.
11.
RayWADaughertyJRGriffinMR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev. 2002;8:276-279.
12.
RejnmarkLOlsenMLJohnsenSPVestergaardPSorensenHTMosekildeL. Hip fracture risk in statin users: a population-based Danish case-control study. Osteoporos Int. 2004;15:452-458. doi:10.1007/s00198-003-1568-z.
13.
RejnmarkLVestergaardPMosekildeL. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif Tissue Int. 2006;79:27-36. doi:10.1007/s00223-006-0024-4.
14.
SchoofsMWSturkenboomMCvan der KliftMHofmanAPolsHAStrickerBH. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res. 2004;19:1525-1530. doi:10.1359/JBMR.040607.
15.
ScrantonREYoungMLawlerESolomonDGagnonDGazianoJM. Statin use and fracture risk: study of a US veterans population. Arch Intern Med. 2005;165:2007-2012. doi:10.1001/archinte.165.17.2007.
16.
WangPSSolomonDHMogunHAvornJ. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283:3211-3326.
17.
Helin-SalmivaaraAKorhonenMJLehenkariP. Statins and hip fracture prevention: a population based cohort study in women. PLoS One. 2012;7:e48095. doi:10.1371/journal.pone.0048095.
18.
LaCroixAZCauleyJAPettingerM. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study. Ann Intern Med. 2003;139:97-104. doi:200307150-00009.
19.
van StaaTPWegmanSde VriesFLeufkensBCooperC. Use of statins and risk of fractures. JAMA. 2001;285:1850-1855.
20.
MundyGGarrettRHarrisS. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.
21.
LuisettoGCamozziV. Statins, fracture risk, and bone remodeling. J Endocrinol Invest. 2009;32(4, suppl):32-37.
22.
KajiHKanataniMSugimotoTChiharaK. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res. 2005;37:589-592. doi:10.1055/s-2005-870538.
23.
StaalAFrithJCFrenchMH. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res. 2003;18:88-96. doi:10.1359/jbmr.2003.18.1.88.
24.
MansiIFreiCRPughMJMortensenEM. Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy. 2013;33:615-626. doi:10.1002/phar.1272.
25.
LuhrmanSLehrEHefflinCSaundN. Interface control document describing the case management exchange from BEA to MDR and M2 baseline. Falls Church, VA: Defense Health Services Systems; 2008.
26.
GanttCJNeelyJAVillafanaIAChunCSGharabaghliSM. Analysis of weight and associated health consequences of the active duty staff at a major Naval medical center. Mil Med. 2008;173:434-440.
27.
GeorgeSZChildsJDTeyhenDS. Brief psychosocial education, not core stabilization, reduced incidence of low back pain: results from the Prevention of Low Back Pain in the Military (POLM) cluster randomized trial. BMC Med. 2011;9:128. doi:10.1186/1741-7015-9-128.
28.
EnewoldLBrintonLAMcGlynnKAZahmSHPotterJFZhuK. Oral contraceptive use among women in the military and the general U.S. population. J Womens Health (Larchmt). 2010;19:839-845. doi:10.1089/jwh.2009.1706.
GibsonDHelmickKJaffeM. Traumatic Brain Injury Care in the Department of Defense. Washington, DC: Department of Defense; 2009.
31.
TanCPNgACivilI. Co-morbidities in trauma patients: common and significant. N Z Med J. 2004;117:U1044.
32.
DeyoRACherkinDCCiolMA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
33.
FDA Drug Safety Communication. New Restrictions, Contraindications, and Dose Limitations for Zocor (simvastatin) to Reduce the Risk of Muscle Injury. Silver Spring, MD: Food and Drug Administration; US Department of Health and Human Services; 2011.
34.
BeckerSIchinoA. Estimation of average treatment effects based on propensity scores. Stata J. 2002;2:358-377.
35.
LeuvenESianesiB. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. http://ideas.repec.org/c/boc/bocode/s432001.html. Accessed July 11, 2014.
36.
RobertsWC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106-107.
37.
MansiIFreiCRPughJMakrisUMortensenEM. Association of musculoskeletal conditions, arthropathies, and injuries with statin use: a propensity score-matched analysis. JAMA Intern Med. 2013;173:1318-1326. doi:10.1001/jamainternmed.2013.6184.
38.
ReidIRHagueWEmbersonJ. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet. 2001;357:509-512.
39.
PedersenTRWilhelmsenLFaergemanO. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol. 2000;86:257-262.
40.
TohSHernandez-DiazS. Statins and fracture risk: a systematic review. Pharmacoepidemiol Drug Saf. 2007;16:627-640.
41.
BauerDCMundyGRJamalSA. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004;164:146-152. doi;10.1001/archinte.164.2.146.
42.
YueJZhangXDongBYangM. Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause. 2010;17:1071-1079. doi:10.1097/gme.0b013e3181d3e036.
43.
DormuthCRPatrickARShrankWH. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119:2051-2057.
44.
de VriesFde VriesCCooperCLeufkensBvan StaaTP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol. 2006;35:1301-1308. doi:10.1093/ije/dyl147.
45.
FehilyAMColesRJEvansWDElwoodPC. Factors affecting bone density in young adults. Am J Clin Nutr. 1992;56:579-586.
46.
JohnellOGullbergBKanisJA. Risk factors for hip fracture in European women: the MEDOS study. J Bone Miner Res. 1995;10:1802-1815. doi:10.1002/jbmr.5650101125.
47.
CummingsSRNevittMCBrownerWS. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-774.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
